2-(1-(5-(6,7-dimethoxyquinolin-4-yl)-3-methylpyridin-2-yl)piperidin-4-yl)-propan-2-ol | 1119717-41-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-(1-(5-(6,7-dimethoxyquinolin-4-yl)-3-methylpyridin-2-yl)piperidin-4-yl)-propan-2-ol
• 英文别名: 2-(1-(5-(6,7-Dimethoxyquinolin-4-yl)-3-methylpyridin-2-yl)piperidin-4-yl)propan-2-ol；2-[1-[5-(6,7-dimethoxyquinolin-4-yl)-3-methylpyridin-2-yl]piperidin-4-yl]propan-2-ol
• CAS: 1119717-41-7
• 化学式: C₂₅H₃₁N₃O₃
• 分子量: 421.539
• InChiKey: QDUQCAJNSFRWRL-UHFFFAOYSA-N

物化性质

• 沸点：
  595.2±50.0 °C(Predicted)
• 密度：
  1.173±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  31
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  67.7
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  1-苄基-4-哌啶甲酸乙酯 在 10% Pd/C 、 氢气 作用下， 以 四氢呋喃 、 二甲基亚砜 为溶剂， 生成 2-(1-(5-(6,7-dimethoxyquinolin-4-yl)-3-methylpyridin-2-yl)piperidin-4-yl)-propan-2-ol
  参考文献：
  名称：

  Use of structure based design to increase selectivity of pyridyl-cinnoline phosphodiesterase 10A (PDE10A) inhibitors against phosphodiesterase 3 (PDE3)

  摘要：

  We report our successful effort to increase the PDE3 selectivity of PDE10A inhibitor pyridyl cinnoline 1 using a combination of computational modeling and structural-activity relationship investigations. An analysis of the PDE3 catalytic domain compared to the co-crystal structure of cinnoline analog 1 in PDE10A revealed two areas of structural differences in the active sites and suggested areas on the scaffold that could be modified to exploit those unique structural features. Once SAR established the cinnoline as the optimal scaffold, modifications on the methoxy groups of the cinnoline and the methyl group on the pyridine led to the discovery of compounds 33 and 36. Both compounds achieved significant improvement in selectivity against PDE3 while maintaining their PDE10A inhibitory activity and in vivo metabolic stability comparable to 1. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.09.010

文献信息

• PHOSPHODIESTERASE 10 INHIBITORS
  申请人：Hu Essa

  公开号：US20090062277A1

  公开（公告）日：2009-03-05

  The present invention is directed to certain compounds useful as phosphodiesterase 10 (PDE10) inhibitors that have the formula where R 1 , R 2 , R 3 , R 4 , X, Y and Z are as defined herein, pharmaceutical compositions containing such compounds and processes for preparing such compounds. The invention is also directed to methods of treating diseases mediated by PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.

  本发明涉及一些化合物，这些化合物可用作磷酸二酯酶10（PDE10）抑制剂，其具有以下结构式：其中R1、R2、R3、R4、X、Y和Z如本文所定义，包含这些化合物的药物组合物以及制备这些化合物的方法。该发明还涉及治疗由PDE10介导的疾病的方法，如肥胖、非胰岛素依赖性糖尿病、精神分裂症、躁郁症、强迫症等。
• [EN] PHOSPHODIESTERASE 10 INHIBITORS<br/>[FR] INHIBITEURS DE LA PHOSPHODIESTÉRASE 10
  申请人：AMGEN INC

  公开号：WO2009025823A1

  公开（公告）日：2009-02-26

  The present invention is directed to certain compounds useful as phosphodiesterase 10 (PDE10) inhibitors that have the formula (I), where R1, R2, R3, R4, X, Y and Z are as defined herein, pharmaceutical compositions containing such compounds and processes for preparing such compounds. The invention is also directed to methods of treating diseases mediated by PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.
• Use of structure based design to increase selectivity of pyridyl-cinnoline phosphodiesterase 10A (PDE10A) inhibitors against phosphodiesterase 3 (PDE3)
  作者：Essa Hu、Roxanne K. Kunz、Shannon Rumfelt、Kristin L. Andrews、Chun Li、Stephen A. Hitchcock、Michelle Lindstrom、James Treanor

  DOI：10.1016/j.bmcl.2012.09.010

  日期：2012.11

  We report our successful effort to increase the PDE3 selectivity of PDE10A inhibitor pyridyl cinnoline 1 using a combination of computational modeling and structural-activity relationship investigations. An analysis of the PDE3 catalytic domain compared to the co-crystal structure of cinnoline analog 1 in PDE10A revealed two areas of structural differences in the active sites and suggested areas on the scaffold that could be modified to exploit those unique structural features. Once SAR established the cinnoline as the optimal scaffold, modifications on the methoxy groups of the cinnoline and the methyl group on the pyridine led to the discovery of compounds 33 and 36. Both compounds achieved significant improvement in selectivity against PDE3 while maintaining their PDE10A inhibitory activity and in vivo metabolic stability comparable to 1. (C) 2012 Elsevier Ltd. All rights reserved.